Skip to content

Effects of amino acids on gut functions in healthy lean individuals

The role of the plasma tryptophan to large neutral amino acid ratio in the effects of amino acids on antropyloroduodenal motility, gut hormone release, appetite and energy intake, cognitive function and mood, in healthy lean individuals

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12620001275954
Enrollment
12
Registered
2020-11-25
Start date
2021-02-08
Completion date
2022-12-01
Last updated
2024-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Interventions to manipulate the plasma tryptophan/large neutral amino acids (LNAA) ratio have resulted in conflicting outcomes in relation to appetite, memory and mood. Evaluating the effects of changes in the tryptophan/LNAA ratio, in a standardised fashion, by acute administration of tryptophan and leucine, and across a range of ratios, may shed light on some of these apparent contradictions. Therefore, the aim of our study is to investigate the effects of changes in the plasma tryptophan/LNAA ratio in a standardised fashion, achieved by intraduodenal administration of tryptophan in combination with increasing loads of the LNAA, leucine, on GI functions, associated with appetite regulation, i.e. antropyloroduodenal motility and gut hormone release, and on appetite and energy intake, as well as on cognitive function and mood, in healthy lean individuals.

Interventions

Each participant will be studied on four occasions, separated by at least 3 (and up to 7) days. On each occasion, participants will receive, in randomised, double-blind fashion, 90-min intraduodenal infusions of the following treatments: (i) control solution (saline), (ii) L-tryptophan at 0.15 kcal/min (3.3 g over 90 min), (iii) combination of L-tryptophan at 0.15 kcal/min (3.3 g) with L-leucine at 0.22 kcal/min (5 g), or (iv) combination of L-tryptophan at 0.15 kcal/min (3.3 g) with L-leucine a

Each participant will be studied on four occasions, separated by at least 3 (and up to 7) days. On each occasion, participants will receive, in randomised, double-blind fashion, 90-min intraduodenal infusions of the following treatments: (i) control solution (saline), (ii) L-tryptophan at 0.15 kcal/min (3.3 g over 90 min), (iii) combination of L-tryptophan at 0.15 kcal/min (3.3 g) with L-leucine at 0.22 kcal/min (5 g), or (iv) combination of L-tryptophan at 0.15 kcal/min (3.3 g) with L-leucine at 0.45 kcal/min (10 g). On study days, participants will arrive in the Clinical Research Facility, and will be intubated with a custom-built, soft, silicon manometric catheter (outer diameter: 4 mm; Dentsleeve International, Mui Scientific, Mississauga, Ontario, Canada) that will be inserted through an anaesthetised nostril and allowed to pass through the stomach and into the duodenum by peristalsis. An intravenous cannula will also be placed into a forearm vein for regular blood sampling. Once the catheter has been positioned correctly, fasting motility will be monitored continuously, and immediately after the end of phase III activity of the fasting migrating motor complex, during a period of motor quiescence (i.e. at t = -10 to 0 min), a 10-ml blood sample (baseline) will be taken, and the participant will complete a visual analogue scale questionnaire (VAS) to assess appetite-related perceptions (fullness, hunger, etc.) and GI symptoms (nausea and bloating), the positive and negative affect schedule-short form (PANAS-SF) questionnaire to assess mood, the N-back test and word recall memory test to assess memory, and the Rapid Visual Information Processing (RVIP) test to measure sustained attention. Estimated times required to complete the questionnaires and tests are ~2 min for VAS and PANAS-SF, 2 min for N-back and word recall memory, and 6 min for RVIP. At t = 0 min, the intraduodenal infusion will commence. APD pressures will be measured continually over the 90-min period. Blood samples and VAS ratings will be collected every 15 min from t = 15 to 90 min. PANAS-SF questionnaires will be completed every 30 min from t = 30 to 90 min. The N-back, word recall memory and RVIP tests will be completed at the end of the infusion, from t = 80 min. At t = 90 min, the manometric assembly will be removed and participants will be presented with a cold, buffet-style meal to assess energy intake. The meal consists of 4 slices (~ 120 g) of whole-meal bread, 4 slices (~ 120 g) of white bread, 100 g sliced ham, 100 g sliced chicken, 85 g sliced cheddar cheese, 100 g lettuce, 100 g sliced tomato, 100 g sliced cucumber, 22 g mayonnaise, 20 g margarine, 1 apple (~ 170 g), 1 banana (~ 190 g), 175 g strawberry yogurt, 100 g chocolate custard, 120 g fruit salad, 375 mL iced coffee, 300 mL orange juice, and 600 mL water. Participants will be allowed 30 min to freely consume food until they are comfortably full. The amount of food (g) consumed will be quantified by weighing each food item of the buffet-meal before and after it was presented to the participant. Energy intake (kcal) will be calculated using commercially available software (Foodworks version 8, Xyris Software, Highgate Hill, Queensland, Australia). At t = 120 min (i.e. at the end of the meal) and at t = 180 min, further blood samples will be taken, and questionnaires administered. The intravenous cannula will then be removed and participants will be allowed to leave the laboratory. Participants will be asked to complete a 24-h dietary record (~2 pm to 2 pm) after each visit to monitor their subsequent energy intake.

Sponsors

Prof. Christine Feinle-Bisset
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
Male
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

Lean (BMI: 19-25 kg/m2) male participants (aged 18-50 years) who are healthy and do not have chronic illnesses will be included.

Exclusion criteria

- regular GI symptoms, as measured by the GI symptom score (score greater than 1 for any component) or significant GI disease or surgery - use of prescribed or non-prescribed medications (including vitamins and herbal supplements) which may affect energy metabolism, GI function, body weight or appetite (eg domperidone, anticholinergic drugs (eg atropine), metoclopramide, erythromycin, hyoscine, orlistat, green tea extracts, Astragalus, St Johns Wort etc.), mood and cognitive function (including benzodiazepines (eg alprazolam), non-benzodiazepine (eg zolpidem), sedatives, antipsychotics (eg aripiprazole), and mood-stabilisers (eg lithium) - regular medication that may affect any of the study outcomes (i.e. GI motor or hormone functions, appetite or mood) and cannot be discontinued during the study - lactose intolerance/other food allergy - current gallbladder or pancreatic disease - coagulation abnormalities - oesophageal varices or strictures - cardiovascular or respiratory diseases that may affect any of the study outcomes and/or tolerance of the naso-duodenal tube - psychological disorders, anxiety and depression, as assessed by the Kessler Psychological Distress Scale (K10) - individuals with low serum ferritin levels (less than 30 µg/L), or who have donated blood in the 12 weeks prior to taking part in the study - any other illnesses as assessed by the investigator (including chronic illnesses that may affect any of the study outcomes and not explicitly listed above) - high performance athletes, due to their specific dietary requirements and energy intakes (i.e. much higher than the average population), which affect GI functions and appetite - current intake of more than 2 standard drinks on more than 5 days per week, due to the known effects of alcohol on GI function, energy intake, mood and cognition - current smokers/users of tobacco products (including pipe, chewing, cigarettes, cigars, sheesha, vaping etc) - recreational drug use (e.g marijuana) - current intake of any illicit substance (since all of these, i.e. tobacco products, marijuana and illicit drugs may affect both GI functions and mood. - vegetarians - restrained eaters (score greater than 12 on the 3-factor eating questionnaire)(the degree of eating restraint will be assessed in obese participants, but not used as an exclusion criterion, as obese often have some degree of eating restraint - diabetes mellitus, as defined by fasting glucose greater than 6.9 mmol/l and/or HbA1c of greater than or equal to 6.5 or less than or equal to 7.9% - inability to tolerate oro/naso-gastric tube - inability to comprehend study protocol

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 6, 2026